Treatment of cancer with novel anti-IL13 monoclonal antibodies
US8318160B2 · kind B2 · utility
20Cited by
30References
51Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2010 |
| Grant date | Nov 27, 2012 |
| Priority date | — |
| Expiry date | May 12, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies. The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.